DCGI shows green flag to Mylan TB drug Pretomanid
The Drug Controller General of India (DCGI) has approved Pretomanid for conditional access under the National Tuberculosis Elimination Program(NTEP), Mylan said in a statement.;
Advertisement
New Delhi: Drug firm Mylan on Wednesday said it has received approval from the Indian drug regulator for anti-tuberculosis drug Pretomanid, developed specifically for drug-resistant forms of the disease.
The Drug Controller General of India (DCGI) has approved Pretomanid for conditional access under the National Tuberculosis Elimination Program (NTEP), Mylan said in a statement.
Through the conditional access approval from DCGI, Mylan will initially make its Pretomanid available in India through a donation of 400 treatment courses to the NTEP, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.